Skip to main content

Onconova Therapeutics, Inc. (ONTX)

NASDAQ: ONTX · IEX Real-Time Price · USD
3.47
+0.01 (0.29%)
After-hours:Oct 22, 2021 7:50 PM EDT
3.46
-0.15 (-4.16%)
At close: Oct 22, 4:00 PM
Market Cap71.90M
Revenue (ttm)236,000
Net Income (ttm)-21.62M
Shares Out15.78M
EPS (ttm)-1.58
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume692,320
Open3.61
Previous Close3.61
Day's Range3.40 - 3.64
52-Week Range3.40 - 28.95
Beta1.82
AnalystsBuy
Price Target11.50 (+232.4%)
Est. Earnings DateNov 11, 2021

About ONTX

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressiv...

IndustryPharmaceuticals
IPO DateJul 25, 2013
CEOSteven Fruchtman
Employees11
Stock ExchangeNASDAQ
Ticker SymbolONTX
Full Company Profile

Financial Performance

In 2020, ONTX's revenue was $231,000, a decrease of -89.42% compared to the previous year's $2.18 million. Losses were -$25.16 million, 17.0% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ONTX stock is "Buy." The 12-month stock price forecast is 11.50, which is an increase of 232.37% from the latest price.

Price Target
$11.50
(232.37% upside)
Analyst Consensus: Buy

News

Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock

NEWTOWN, Pa., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products ...

3 weeks ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Onconova (ONTX) Stock?

Investors need to pay close attention to Onconova (ONTX) stock based on the movements in the options market lately.

4 weeks ago - Zacks Investment Research

Onconova Therapeutics Raises $21M Via Equity At 17% Discount

Onconova Therapeutics Inc (NASDAQ: ONTX) has priced an underwritten public offering of 5 million shares at $4.20 for gross proceeds of $21 million. The offer price represents an almost 17% discount at t...

4 weeks ago - Benzinga

Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock

NEWTOWN, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer...

4 weeks ago - GlobeNewsWire

Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

NEWTOWN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer...

1 month ago - GlobeNewsWire

Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer

Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control po...

1 month ago - Zacks Investment Research

Why Onconova Therapeutics Shares Are Surging Today

Onconova Therapeutics, Inc. (NASDAQ:ONTX) shares are trading higher after the company reported preliminary data from a Phase 1/2 a trial of rigosertib plus immune checkpoint inhibitor nivolumab, which a...

1 month ago - Benzinga

ONTX Stock Is Soaring 25% on This Big Cancer Drug Update

Today, Oncova Therapeutics announced some positive preliminary trial results from one of its core cancer drugs, sending ONTX stock higher. The post ONTX Stock Is Soaring 25% on This Big Cancer Drug Upda...

1 month ago - InvestorPlace

Investors Cheer Onconova's Rigosertib Combo Data In Lung Cancer Setting

Onconova Therapeutics Inc (NASDAQ: ONTX) has announced preliminary data from Phase 1/2a trial of rigosertib plus Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in advanced KRAS mutated non-sma...

1 month ago - Benzinga

Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Tops Revenue Estimates

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 3.57% and 35.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Recap: Onconova Therapeutics Q2 Earnings

Shares of Onconova Therapeutics (NASDAQ:ONTX) moved higher by 2.1% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 575.00% over the past year to ...

2 months ago - Benzinga

Onconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today

2 months ago - GlobeNewsWire

How to Pick the Best Small Cap Biotech Stocks to Buy

Investing in biotech stocks isn't for the faint of heart, but these can be some of the most lucrative equities on the market. The post How to Pick the Best Small Cap Biotech Stocks to Buy appeared first...

Other symbols:KMPHNOVNSAVA
2 months ago - InvestorPlace

Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021

Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 12. Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 12.

2 months ago - GlobeNewsWire

Will Onconova Therapeutics, Inc. (ONTX) Report Negative Q2 Earnings? What You Should Know

Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Sma...

Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration

3 months ago - GlobeNewsWire

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

NEWTOWN, Pa., June 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients wit...

4 months ago - GlobeNewsWire

Onconova Therapeutics, Inc. (ONTX) Upgraded to Buy: What Does It Mean for the Stock?

Onconova Therapeutics, Inc. (ONTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 months ago - Zacks Investment Research

Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300

Phase 1 study to evaluate ON 123300 in advanced cancer patients including HR+ HER 2- metastatic breast cancer patients resistant to approved CDK 4/6 inhibitors Phase 1 study to evaluate ON 123300 in adv...

5 months ago - GlobeNewsWire

Top Penny Stocks to Buy Now? 4 Big Movers to Watch Today

Are these the top penny stocks to buy in 2021? Take a look and decide for yourself The post Top Penny Stocks to Buy Now?

Other symbols:AEHRIMMPUXIN
5 months ago - PennyStocks

Onconova Therapeutics Announces Reverse Stock Split and Decrease in Authorized Shares

NEWTOWN, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing ...

5 months ago - GlobeNewsWire

Why Onconova Therapeutic's Is Surging Today

Onconova Therapeutics, Inc. (NASDAQ: ONTX) shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and $4 price target. Onconova Therapeutics is a biopharmaceutical ...

5 months ago - Benzinga

Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5

Biotech penny stocks continue to heat up; here's 4 under $5 to look into The post Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News an...

Other symbols:ACRXAGEN
5 months ago - PennyStocks

Onconova Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today

5 months ago - GlobeNewsWire

Penny Stocks to Buy in May 2021? Here's 3 Big Pre-Market Gainers

These penny stocks moved big in early morning trading; here's why The post Penny Stocks to Buy in May 2021? Here's 3 Big Pre-Market Gainers appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other symbols:IDEX
5 months ago - PennyStocks